Bioventus (BVS) Amortization of Deferred Charges (2020 - 2021)
Bioventus (BVS) reported Amortization of Deferred Charges of $136000.0 for Q2 2021, little changed on a YoY basis from $136000.0 in Q2 2020, and little changed quarter-over-quarter from $136000.0 in Q1 2020.
Bioventus (BVS) Amortization of Deferred Charges (2020 - 2021) Analysis & Trends
Bioventus has reported Amortization of Deferred Charges for 2 years, with the latest figure at $136000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn |
| 10 | Bioventus | 571.68 Mn | 581.20 Mn | 90.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2021 | 136,000.00 |
| Apr 3, 2021 | 136,000.00 |
| Mar 28, 2020 | 136,000.00 |
| Mar 28, 2020 | 136,000.00 |